Wal-Mart (NYSE:WMT) has made a lot of efforts in pricing its goods attractively over the past months. This allowed for strong traffic growth, which resulted in positive comps for the company. Subsequently, Wal-Mart’s shares have been performing much better than those of its peers, which are reporting worse comp sales. Due to Wal-Mart’s power when it comes to discussing prices with its suppliers, the company is able to price its goods attractively whilst generating strong margins, which, in turn, means that the earnings power of Wal-Mart remains high (despite the low prices Wal-Mart offers its goods at), which makes Wal-Mart a compelling retail investment.
Best Low Price Stocks To Invest In Right Now: Platinum Group Metals Ltd.(PLG)
- [By William Patalon III]
Our sub-$2 “Gold Market Anomaly” play – Platinum Group Metals Ltd. (NYSE: PLG) – took a hit of more than 12% Wednesday after the miner raised $20 million through a stock offering.
Best Low Price Stocks To Invest In Right Now: Vuzix Corporation(VUZI)
- [By James E. Brumley]
While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.
These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.
One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.
It’s not been a smooth beginning. however.
While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.
Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.
On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.
Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an
- [By William Patalon III]
Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.
- [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
Best Low Price Stocks To Invest In Right Now: Inovio Pharmaceuticals, Inc.(INO)
- [By Jim Robertson]
On Tuesday, small capInovio Pharmaceuticals (NASDAQ: INO) surged 22.63% after announcingthat its synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last 100 years. This includesthe virus that caused Spanish Flu in 1918. The study involvedmultiple animal models, including mice, guinea pigs and non-human primates. Given how bad flu season is this year, the announcement got plenty of attention asthe following technical chart shows:
- [By Ben Levisohn]
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.
In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.
Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s DNA-based vaccine approach is safe and can rapidly transition to human studies.
Shares of Inovio Pharmaceuticalshave gained 4.3% to $9.24 at 2:50 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.3% to $284.29.
- [By Lisa Levin]
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were also up, gaining 24 percent to $8.84 following announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response.
- [By Keith Speights]
A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.
Best Low Price Stocks To Invest In Right Now: Maximus, Inc.(MMS)
- [By Michael Flannelly]
Analysts at Jefferies initiated coverage on business process services provider Maximus Inc. (MMS) late on Thursday, giving the stock a bullish rating because it has several competitive advantages and should benefit from the Affordable Care Act (Obamacare).
The analysts rate MMS as “Buy” and see shares reaching $47. This price target suggests a 20% upside to the stock’s Thursday closing price of $39.14.
“MMS is a leading government outsourced contractor that produces consistently strong results,” Jefferies analyst David Styblo commented. “The company has several competitive advantages and is highly focused on health and human service projects. This positions MMS to enjoy multi-year growth from the ACA and other opportunities with limited risk. The company’s predictable business model, solid balance sheet, and EPS visibility into FY2014 also support a Buy and $47 PT.”
Maximus shares were inactive during pre-market trading on Friday. The stock is up 23.83% year-to-date.
- [By ]
Maximus Inc (NYSE: MMS) holds just $16 million in long-term debt against $886 million in shareholder equity. Shares trade for 1.7 times sales for a discount of 26% on the industry average of 2.3 times sales.
Best Low Price Stocks To Invest In Right Now: Lexicon Pharmaceuticals, Inc.(LXRX)
- [By Paul Ausick]
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) dropped about 12.3% Wednesday to post a new 52-week low of $12.93 after closing at $14.74 on Tuesday. The stock’s 52-week high is $19.62. Volume of around 2.8 million was nearly 5 times the daily average. The company had no specific news.